Speciality: Gynaecological surgical oncology
Sub specialities: Surgical Oncology, Complex Pelvic Surgery
Dr James P Beirne is one of the few surgical oncologists in the UK and Ireland who is dual-clinical fellowship trained and, formally, dual-clinical academic trained. He completed general training in Obstetrics and Gynaecology in Northern Ireland. He also completed a Clinical Research Fellowship, with the support of the Northern Ireland Public Health Agency Research and Development Department, for which he was awarded a PhD for investigating the underlying molecular biology of high grade serous tubo-ovarian carcinoma. Following this, Dr Beirne embarked upon a combined, GMC-approved, Clinical Academic Training Lectureship and an RCOG-approved Sub-Specialty Training Fellowship in Gynaecological Oncology at Queen’s University, Belfast and the Northern Ireland Centre for Gynaecological Cancer. He also completed an Advanced Training Fellowship in Gynaecological Surgical Oncology at the Queensland Centre for Gynaecological Cancer in Brisbane, Australia.
Irish Medical Council (registration number: 429644)
General Medical Council (registration number: 6143943)
Colleges and Societies.
Member of Royal College of Obstetricians and Gynaecologists.
Member of the British Gynaecological Cancer Society.
Member of the British Society of Colposcopy & Cervical Pathology.
Member of the Irish Society of Gynaecological Oncology.
Member of the Ulster Obstetrical and Gynaecological Society.
Associate Member of the International Gynaecological Cancer Society.
Member of European Society of Surgical Oncology.
Member of European Society of Gynaecological Oncology.
Founding Member of the Audit & Research in Gynaecological Oncology Collaborative.
Member of Clinical Trials Ireland.
Throughout his sub-specialist and Advanced Fellowship Training, Dr Beirne maintained an integral role in translational research at the Patrick G Johnston Centre for Cancer Research, Queen’s University, Belfast. This resulted in the development of a bespoke research programme focussed on the identification and validation of biomarkers for ovarian cancer.